BioXcel Therapeutics (BTAI) Misses Q4 EPS by 58c
Tweet
Share
E-mailGet Alerts BTAI Hot Sheet
Join SI Premium – FREE
BioXcel Therapeutics (NASDAQ: BTAI) reported Q4 EPS of ($0.58). Revenue for the quarter came in at $260 thousand.
For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James cuts Delta and JetBlue ratings ahead of Q2 earnings
- DA Davidson Downgrades Regions Financial (RF) to Neutral on Potential Revenue Shortfall
- Buy the pullback in chip stocks, JPM's Matejka says
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
